Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity (Deficit)

v3.21.2
Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at the beginning of the period at Sep. 30, 2019 $ 172,612 $ 37,885,151 $ (38,865,060) $ (807,297)
Balance at the beginning of the period (in shares) at Sep. 30, 2019 172,612,233      
Net loss $ 0 0 (4,691,377) (4,691,377)
Issuance of common stock and warrants, net of financing costs $ 14,286 2,152,876 0 2,167,162
Issuance of common stock and warrants, net of financing costs (in shares) 14,285,714      
Shares issued for the exercise of stock options $ 5,182 927,546 0 932,728
Shares issued for the exercise of stock options (in shares) 5,181,819      
Issuance of restricted stock $ 965 (965) 0 0
Issuance of restricted stock (in shares) 965,000      
Stock based compensation expense $ 0 898,293 0 898,293
Balance at the ending of the period at Sep. 30, 2020 $ 193,045 41,862,901 (43,556,437) $ (1,500,491)
Balance at the ending of the period (in shares) at Sep. 30, 2020 193,044,766     193,044,766
Net loss $ 0   (6,240,482) $ (6,240,482)
Issuance of common stock and warrants, net of financing costs $ 43,125 6,176,108   6,219,233
Issuance of common stock and warrants, net of financing costs (in shares) 43,125,004      
Vesting of restricted stock issued $ 550 (550)    
Vesting of restricted stock issued (in shares) 550,000      
Stock based compensation expense   496,066   496,066
Balance at the ending of the period at Sep. 30, 2021 $ 236,720 $ 48,534,525 $ (49,796,919) $ (1,025,674)
Balance at the ending of the period (in shares) at Sep. 30, 2021 236,719,770     236,719,770